Dec 05, 2016 18:01 pm UTC| Business
-- PRO designed to establish clinical benefit – -- First time a PRO to be used as a secondary clinical endpoint in a SCD registrational study -- --Company to Host Webcast Today at 12:15 p.m. PT to Discuss ASH Data...
Global Traveler Names TAP Portugal “Best Airline in Europe” for Sixth Consecutive Year
Dec 05, 2016 18:00 pm UTC| Business
NEW YORK, Dec. 05, 2016 -- TAP Portugal was honored by Global Traveler magazine with the awards for "Best Airline in Europe," for the sixth consecutive year, and "Best New Route Launch (Boston-Lisbon)," awarded in the...
Dec 05, 2016 18:00 pm UTC| Business
SAN DIEGO, Dec. 05, 2016 -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the...
Dec 05, 2016 17:48 pm UTC| Business
NEW YORK, Dec. 05, 2016 -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially pivotal clinical trial in blastic...
American Health Council Names Janet Allan, PhD, APRN, FAAN to Education Board
Dec 05, 2016 17:11 pm UTC| Business
NEW YORK, Dec. 05, 2016 -- Dr. Janet Allan, Dean Emeritus at the University of Maryland, Baltimore, has been selected to join the Education Board at the American Health Council. She will be sharing her knowledge and...
Powersim Releases PSIM v11.0 With Extensive Functionalities, Including a New Spice Engine
Dec 05, 2016 17:00 pm UTC| Business
ROCKVILLE, Md., Dec. 05, 2016 -- Powersim is pleased to announce the release of PSIM v11.0, with the addition of extensive new features, including a new SPICE engine. PSIM v11.0 is now more powerful than ever. The...
Sustained Clinical Benefit After 3 Year Follow Up in Scleroderma Trial
Dec 05, 2016 16:30 pm UTC| Business
SAN DIEGO, Dec. 05, 2016 -- Cytori Therapeutics, Inc.(NASDAQ:CYTX) Topline review of early three-year follow-up data from the SCLERADEC I trial shows sustained benefit in treated patients over baseline in major study...